Alterity Therapeutics Limited
Alterity Therapeutics Limited
Your view on PRNAF
Overview
What the company does, where it operates, and who runs it.
About Alterity Therapeutics Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- David A. Stamler
- Headquarters
- 460 Bourke Street, Melbourne, VIC, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- David A. Stamler
- Headquarters
- 460 Bourke Street, Melbourne, VIC, AU
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease.
It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Alterity Therapeutics Limited, and the rating behind it. PRNAF last traded at $0.01; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Alterity Therapeutics Limited. Starting points for Alterity Therapeutics Limited: EPS -$0.11, beta -0.02 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Alterity Therapeutics Limited. Alterity Therapeutics Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Alterity Therapeutics Limited. Trailing twelve-month EPS for Alterity Therapeutics Limited stands at -$0.11. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Alterity Therapeutics Limited. Alterity Therapeutics Limited has reported as a listed company since 2012. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Alterity Therapeutics Limited valued side by side against its closest peers. Alterity Therapeutics Limited is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Alterity Therapeutics Limited, and how their positions are changing. At a $109.8M market value, institutional positions materially move Alterity Therapeutics Limited's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Alterity Therapeutics Limited executives and directors. Shares of Alterity Therapeutics Limited have traded between $0.0030 and $0.01 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Alterity Therapeutics Limited. Alterity Therapeutics Limited is a $109.8M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Alterity Therapeutics Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Alterity Therapeutics Limited. Coverage tracks Alterity Therapeutics Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.